Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, has seen its stock price touch a 52-week low, dipping to $9.25. This latest price movement underscores a challenging period for the company, with a 1-year decline of 11.55%. According to InvestingPro analysis, the stock appears undervalued, with a market cap of $13.4 billion and an attractive EV/EBITDA ratio of 6x. Investors are closely monitoring Viatris as it navigates through market pressures and seeks to establish a stronger foothold within the competitive pharmaceutical industry. InvestingPro data reveals management’s aggressive share buyback program and projects net income growth this year, with analysts forecasting EPS of $2.69 for 2024. The company maintains a healthy current ratio of 1.51 and offers a 4.27% dividend yield. The 52-week low serves as a critical indicator for the company’s performance and investor sentiment over the past year, marking a phase of heightened scrutiny and expectation for strategic initiatives that could potentially rejuvenate Viatris’s market position. For deeper insights, check out the comprehensive Pro Research Report available on InvestingPro, which includes 5 additional exclusive ProTips.
In other recent news, Viatris Inc. reported its fourth-quarter earnings and revenue, which fell short of analyst expectations. The company posted adjusted earnings per share of $0.54, missing the consensus estimate of $0.58. Revenue for the quarter was $3.52 billion, below Wall Street’s projection of $3.62 billion. For the full year 2024, Viatris reported total revenues of $14.7 billion and an adjusted EBITDA of $4.7 billion, with an adjusted EPS of $2.65. Looking ahead, Viatris provided guidance for 2025, forecasting revenue between $13.5 billion and $14 billion, which is less than the $14.22 billion analysts had anticipated. The company’s adjusted EPS guidance for 2025 is projected to be between $2.12 and $2.26, also falling short of the $2.59 consensus. Viatris attributed part of the expected shortfall to an FDA warning letter and import alert at its Indore, India facility, estimating a $500 million reduction in 2025 revenues and a $385 million decrease in adjusted EBITDA. CEO Scott A. Smith noted that while 2024 showed operational revenue growth, the outlook for 2025 suggests potential challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.